No annual revenue total was found in ACTUATE THERAPEUTICS, INC.'s SEC filings.
Actuate Therapeutics, Inc. (ACTU) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-20.45M
+17.1% vs year-ago TTM
Operating cash flow (TTM)
$-19.84M
+12.7% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-0.89
+37.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
23.71M
+21.4% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACTU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Worth, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1652935
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Operating income | -$22.5M | -$25.2M |
| Net income | -$22.2M | -$27.3M |
| Diluted EPS | -$1.06 | -$3.26 |
| Operating cash flow | -$19.2M | -$21.8M |
| Total assets | $14.0M | $9.3M |
| Total liabilities | $6.1M | $9.2M |
| Stockholders' equity | $7.9M | $104,186 |
| Cash and investments | $13.2M | $8.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 28, 2026 | Oct 26, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 17, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
All 192 Actuate Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.